Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Treasury Shares (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Treasury Shares for 2 consecutive years, with $220500.0 as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 292.0% to $220500.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $220500.0 through Dec 2025, up 292.0% year-over-year, with the annual reading at $220500.0 for FY2025, 292.0% up from the prior year.
  • Treasury Shares hit $220500.0 in Q4 2025 for Prelude Therapeutics, down from $292375.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $384875.0 in Q1 2025 to a low of $56250.0 in Q4 2024.